Gene:
EDIL3
EGF-like repeats and discoidin I-like domains 3

PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB has no annotated drug labels with pharmacogenomic information for this . If you know of a drug label with PGx, send us a message.

PharmGKB contains no Clinical Variants that meet the highest level of criteria.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

This is a non-comprehensive list of genetic tests with pharmacogenetics relevance, typically submitted by the manufacturer and manually curated by PharmGKB. The information listed is provided for educational purposes only and does not constitute an endorsement of any listed test or manufacturer.

A more complete listing of genetic tests is found at the Genetic Testing Registry (GTR).

PGx Test Variants Assayed Related Drugs?

Overview

Alternate Names:  None
Alternate Symbols:  DEL1
PharmGKB Accession Id: PA27613

Details

Cytogenetic Location: chr5 : q14.3 - q14.3
GP mRNA Boundary: chr5 : 83238126 - 83680611
GP Gene Boundary: chr5 : 83235126 - 83690611
Strand: minus
The mRNA boundaries are calculated using the gene's default feature set from NCBI, mapped onto the UCSC Golden Path. PharmGKB sets gene boundaries by expanding the mRNA boundaries by no less than 10,000 bases upstream (5') and 3,000 bases downstream (3') to allow for potential regulatory regions.

PharmGKB Curated Pathways

Pathways created internally by PharmGKB based primarily on literature evidence.

PharmGKB contains no curated pathways for this gene. If you would like to volunteer to work on a pathway, please let us know.

External Pathways

Links to non-PharmGKB pathways.

  1. Integrins in angiogenesis - (Pathway Interaction Database NCI-Nature Curated)

LinkOuts

Entrez Gene:
10085
OMIM:
606018
UCSC Genome Browser:
NM_005711
RefSeq RNA:
NM_005711
RefSeq Protein:
NP_005702
RefSeq DNA:
AC_000048
AC_000137
NC_000005
NT_006713
NW_001838951
NW_922729
UniProtKB:
EDIL3_HUMAN (O43854)
Q8N610_HUMAN (Q8N610)
Ensembl:
ENSG00000164176
GenAtlas:
EDIL3
GeneCard:
EDIL3
MutDB:
EDIL3
ALFRED:
LO002143K
HuGE:
EDIL3
Comparative Toxicogenomics Database:
10085
ModBase:
O43854
HumanCyc Gene:
HS09035
HGNC:
3173

Common Searches